Crossmark

The long-term impact of early treatment of multiple sclerosis on the risk of disability pension

Crossref DOI link: https://doi.org/10.1007/s00415-018-8764-4

Published Online: 2018-02-01

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Landfeldt, Erik https://orcid.org/0000-0002-5758-7151
Castelo-Branco, Anna

Svedbom, Axel

Löfroth, Emil

Kavaliunas, Andrius

Hillert, Jan
Funding

Funding for this research was provided by:

Novartis
License Information

Text and Data Mining valid from 2018-02-01
More Information

Article History

Received: 22 November 2017

Revised: 12 January 2018

Accepted: 23 January 2018

First Online: 1 February 2018

Compliance with ethical standards

:

: Dr. Erik Landfeldt, Dr. Anna Castelo-Branco, and Mr. Axel Svedbom are consultants to Novartis through their employment at Mapi Group. Mr. Emil Löfroth is an employee and shareholder of Novartis. Dr. Andrius Kavaliunas reports no conflicts of interest. Dr. Jan Hillert has received honoraria for serving on advisory boards for BiogenIdec and Novartis, speaker’s fees from BiogenIdec, Merck-Serono, Bayer-Schering, Teva, and Sanofi-Aventis, and has served as investigator for projects sponsored by, or received unrestricted research support from, BiogenIdec, Merck-Serono, TEVA, Novartis, and Bayer-Schering.

: The study ethical approval was granted by the Regional Ethical Review Board in Stockholm, Sweden.

: Patient identifiers were encrypted.